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Abstract

Background: Abnormal uterine bleeding (AUB) affects *1.4 million women in the United States each year.
This study sought to identify differences in treatment decisions for managing noncancer-related AUB.
Materials and Methods: IRB approval was obtained. This retrospective study analyzed data for all women 21–
60 years old, diagnosed with AUB from July 1, 2013 through June 30, 2017, in an Obstetrics and Gynecology
residents’ clinic serving mostly underinsured patients. Patients with a diagnosis of postmenopausal bleeding or
any gynecologic cancer were excluded. Two multivariable logistic regression models were used to identify
variables independently associated with receiving surgical (vs. medical) treatment and any (vs. no) treatment.
Results: Of 2,154 patients with AUB, 1,705 women met all inclusion criteria and had complete data for
analysis. In the model examining receipt of surgical (vs. medical) treatment, women ages 41–60 were 4.8 times
more likely than women 21–40 years old to receive surgical treatment. Women designated as ‘‘Other’’ (nonWhite) race/ethnicity were 80.8% less likely than Black/African American patients to receive surgery. Body
mass index (BMI) and insurance type were not independently associated with receiving surgical treatment. In
the model examining any (vs. no) treatment, women ages 41–60 (vs. 21–40) and of unknown (vs. Black/African
American) race/ethnicity were 69.6% and 50.8% less likely to receive any treatment, respectively. BMI and
insurance status were not independently associated with receiving any treatment.
Conclusion: Management of AUB differed significantly by age and race/ethnicity, but not BMI or insurance.
Further investigation among larger diverse populations is warranted to test the generalizability of these findings.
Keywords: abnormal uterine bleeding, health disparities, race/ethnicity, obesity, treatment decisions

Introduction

I

n the United States, abnormal uterine bleeding (AUB)
affects *1.4 million women each year.1 AUB can be
secondary to a wide array of anatomic and physiologic
problems such as ovulatory dysfunction, uterine fibroids,
endometrial polyps, and bleeding disorders. Women with
AUB report health-related quality-of-life scores below the
25th percentile on key domains such as physical functioning,
vitality, pain, and mental health.2 In addition to these negative health outcomes, AUB has an estimated direct economic
burden of *$1 billion per year.2
While there are international guidelines for the diagnosis
of AUB,3 the choice of medical or surgical treatment is largely guided by the individual provider’s approach depending

on presumptive etiology, patient preference, provider judgment, and provider bias. Multiple medical therapeutic options are available, effective, and are often recommended
as first-line treatments over a surgical approach.3–5 In a study
of trade-offs of four treatment options using a hypothetical
cohort of premenopausal women with heavy menstrual
bleeding and no evidence of malignancy, the levonorgestrelreleasing intrauterine device (LNG-IUD) option demonstrated superior outcomes with regard to quality-adjusted life
years and cost than hysterectomy and uterine ablation.6 In a
review of management options for AUB, surgical approaches, including hysterectomy, should be reserved for
women with an anatomic cause for bleeding or whose
bleeding does not improve with medical management.7
However, a recent study found that, among women who
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underwent hysterectomy for uterine fibroids, endometriosis,
or pelvic pain, no alternative treatment was documented in
*40% of cases.8 Women who were <40 years old and White
were more likely to have documentation of nonsurgical
treatment compared with women who were ‡40 and classified as Black/African American and from other racial/ethnic
groups.8 In addition, Lee et al. found women to be more likely
to receive a laparoscopic hysterectomy than other modes of
hysterectomy if they were <35 years, White, in the highest
median income group, or had private insurance.9,10
Analyses of differences in care for AUB have focused on
specific diagnoses such as uterine fibroids and endometriosis;
these studies primarily examined differences in surgical approaches.11–16 However, decisions regarding treatment are
often made on a presumptive clinical diagnosis without
conclusive preoperative evidence of the underlying etiology
or postoperative supporting pathology.8 Studies have identified clear racial and ethnic differences in the incidence,
management, and outcomes of some but not all specific etiologies of AUB such as uterine fibroids.11–14 Currently, there
is no research addressing differences in care for the broad
diagnosis of AUB. The current literature lacks an analysis of
differences in clinical decision-making and treatment options
in the face of uncertain etiologies of benign AUB before the
establishment of pathologic diagnosis.8
The objective of this study was to describe differences in
treatment decisions for the management of noncancer-related
AUB among women seen in an Obstetrics & Gynecology
(OBGYN) residents’ clinic serving mostly Medicaid or uninsured patients. We hypothesized that differences in treatment decisions would be observed by age, race/ethnicity,
body mass index (BMI), and insurance type.
Materials and Methods

After receiving approval of our Institutional Review Board,
a retrospective descriptive study of existing data was performed at the institution’s OBGYN resident clinic. This clinic
is an urban, Midwest academic referral center and a safety-net
hospital serving largely low-income African American women. Resident-clinic patients are managed through joint
decision-making discussion between the onsite academic
faculty and the individual resident. All patients who were seen
in the resident clinic from July 1, 2013 through June 30, 2017
were potentially eligible for inclusion in the study. Women of
reproductive age with a diagnosis of AUB were identified
for inclusion using International Classification of Diseases
(ICD)-9 and ICD-10 codes (Supplementary Table S1). Patients
<21 years and >60 years at their first appointment during the
study period were excluded as were any patients with a diagnosis of gynecologic cancer based on ICD-9 and ICD-10 codes
(Supplementary Table S2).
For patients with AUB meeting our inclusion criteria, demographic information regarding age at first visit in the study
period, race/ethnicity, BMI, and insurance status was collected
from the resident-clinic database. Treatment information was
collected from our billing data and medical records, and then
categorized into medical treatment, surgical treatment, or no
treatment. To classify receipt of medical treatment, a list of
medications available in our clinic during the study period that
could be utilized in the treatment of AUB was created and used
to audit medical records. Medical treatment included tra-
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nexamic acid and reproductive hormone therapy in various
routes of administration, including pill, patch, or ring forms of
estrogens and/or progestins. We also included depotmedroxyprogesterone acetate, depot leuprolide, subdermal
levonorgestrel implant, and LNG-IUD. We also included
current procedural terminology (CPT) codes for insertion and/or removal of any IUD as medical management, as CPT
coding does not distinguish hormonal from nonhormonal
IUDs. Because all women in our study group had AUB, we
presumed that IUD insertion or removal during the study period that was not additionally coded for contraception was
involved in the AUB treatment plan, either to insert a hormonal
IUD to treat AUB or to remove either a copper or hormonal
IUD due to bleeding. Those AUB patients who received one or
more of the aforementioned drugs or had insertion and/or removal of an IUD during the study period were identified and
categorized as having medical treatment.
Information regarding surgical treatment for AUB was
obtained using CPT codes corresponding to any type of
hysterectomy, endometrial ablation, myomectomy, and
uterine artery embolization (Supplementary Table S3). Patients who underwent any of these surgical procedures were
classified as having surgical treatment for AUB, whether
medical treatment was also given to these patients. Hysteroscopy, which in our population was always accompanied
by a dilation and curettage, was considered diagnostic and not
surgical treatment. Although polypectomies are performed as
a surgical treatment for AUB, the CPT code for hysteroscopy
with polypectomy is the same as that for hysteroscopy with
sampling and thus indistinguishable from a diagnostic procedure (CPT code 58558). Finally, those AUB patients with
neither medical nor surgical treatments recorded were categorized as having no treatment for AUB. This group included
women who were intentionally observed and had spontaneous resolution, who might have declined recommended
treatment, whose evaluation was not completed during the
study period, or who were lost to follow-up.
Demographic characteristics of our sample include age,
race/ethnicity, and insurance status. Age was categorized as
21–40 and 41–60 years. For analysis, race/ethnicity was
categorized as Black/African American, White, Other, or
Unknown. The Other category included patients designated
as ‘‘Other,’’ Asian, Native Hawaiian/Pacific Islander, Native
American/Alaska Native, ‘‘Multi-racial,’’ and Hispanic ethnicity. The Unknown race/ethnicity category included patients who were missing data or designated as ‘‘Unknown’’ or
‘‘Declined.’’ Insurance status was categorized as public (e.g.,
Medicaid or Medicare), private, and self-pay.
BMI in kg/m2 was calculated for each woman with weight
and height data, and classified using the Centers for Disease
Control and Prevention (CDC) overweight and obesity categories.17 For analysis, BMI was grouped into four categories: BMI <25 kg/m2 (underweight/normal weight), 25 to
<30 kg/m2 (overweight), 30 to <40 kg/m2 (Class 1 and Class 2
obesity), and ‡40 kg/m2 (Class 3–5 obesity). We combined
the CDC Class 1 and 2 obesity groups17 due to the relatively
small numbers in each of these subgroups.
Statistical analyses were performed using IBM SPSS
Statistics version 25 (IBM Corp., Armonk, NY, USA). We report descriptive statistics for characteristics of our sample and
type of treatment received. Associations among categorical
variables were assessed using chi-square tests. Two-tailed
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p-values <0.05 were considered significant. Separate multivariable logistic regression models were used to identify variables
that were independently associated with the probability of receiving (1) surgical (vs. medical) treatment, and (2) any medical
or surgical treatment (vs. no treatment). We report adjusted odds
ratios and 95% confidence intervals. A post hoc power analysis
showed that we have >95% power to detect significant differences in a comparison of surgical to medical treatment only and
in comparison of any to no treatment.
Results

Records of all 13,127 women seen in the Barnes-Jewish
Hospital OBGYN Resident clinic from July 1, 2013 through
June 30, 2017 were reviewed. Of the 2,154 women with ICD9/ICD-10 codes consistent with a diagnosis of AUB, we excluded 306 who were <21 years and 19 who were >60 years at
the time of their first resident-clinic visit during the study period, and thus presumptively beyond reproductive age. We
also excluded 45 women with a diagnosis of gynecologic
cancer, 42 women whose BMI could not be determined, and 37
women without insurance status data (Fig. 1). The final sample
of 1,705 women with complete data for analysis was 93.2% of
1,784 resident-clinic patients with a diagnosis of AUB who did
not have a diagnosis of cancer and were 21–60 years of age.
As shown in Table 1, most patients in our study sample
were Black/African American (67.7%), publicly insured
(65.3%), age 21–40 (64.3%), and had a BMI ‡30 kg/m2
(62.6%). The Other race/ethnicity category included a heterogeneous group of 86 patients, 64 of whom were designated in the medical record only as ‘‘Other’’ race; the next
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largest group in this category included 17 Asian women. The
Unknown category included 137 patients, 120 of whom were
missing data. Of all 1,705 patients in our sample, 777 (45.6%)
women received only medical treatment for AUB, 307
(18.0%) received surgical treatment (with or without medical
treatment), and 621 (36.4%) received neither medical nor
surgical treatment for AUB during the study period. In bivariate analyses, there were significant associations between
each of the patient characteristics and treatment received
except for insurance type (Table 1). Furthermore, there were
significant associations among the various patient characteristics (each chi-square p < 0.05), except for the association
between race/ethnicity and age ( p = 0.44; data not shown).
Notably, of 1,149 Black/African American patients, 796
(69.3%) were publicly insured and 753 (65.5%) were obese.
Table 2 shows the results of two multivariable logistic regression models used to identify independent predictors of
surgical (vs. medical) treatment and any (vs. no) treatment. In
the first model, women in the 41–60 age group were more likely
than women in the 21–40 age group to have had surgical (vs.
medical) treatment. The Other race/ethnicity group was less
likely than Black/African American patients to have received
surgical treatment, but women who were White and Unknown
race/ethnicity were as likely as Black/African American women
to have received surgical treatment. Insurance status and BMI
were not independently associated with receipt of surgical (vs.
medical) treatment for AUB in this model.
In the second model, women in the 41–60 age group were
less likely than women in the 21–40 age group to have received any (vs. no) treatment. Women in the Unknown
race/ethnicity group were less likely than Black/African

FIG. 1. Resident clinic
study sample selection process. AUB, abnormal uterine
bleeding; BMI, body mass
index.
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Table 1. Characteristics of the Study Sample of Women with Abnormal Uterine Bleeding Seen
in the Obstetrics & Gynecology Resident-Clinic July 1, 2013 Through June 30, 2017, by Treatment Received
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Characteristics
Age
21–40
41–60
Race/ethnicity
Black/African American
White
Otherb
Unknownc
Insurance type
Public
Self-pay
Private
BMI (kg/m2)
<25
25 to <30
30 to <40
‡40

Total
(N = 1,705) (%)

Surgical
(N = 307) (%)

Medical
(N = 777) (%)

No treatment
(N = 621) (%)

1079 (63.3)
626 (36.7)

122 (39.7)
185 (60.3)

597 (76.8)
180 (23.2)

360 (58.0)
261 (42.0)

1149
336
86
134

215
65
3
24

543
145
46
43

391
126
37
67

pa
<0.001
<0.001

(67.4)
(19.7)
(5.0)
(7.9)

(70.0)
(21.2)
(1.0)
(7.8)

(69.9)
(18.7)
(5.9)
(5.5)

(63.0)
(20.3)
(6.0)
(10.8)
0.208

1143 (67.0)
333 (19.5)
229 (13.4)

218 (71.0)
51 (16.6)
38 (12.4)

499 (64.2)
167 (21.5)
111 (14.3)

426 (68.6)
115 (18.5)
80 (12.9)

36
67
129
75

130
170
256
221

110
128
234
149

0.034
276
365
619
445

(16.2)
(21.4)
(36.3)
(26.1)

(11.7)
(21.8)
(42.0)
(24.4)

(16.7)
(21.9)
(32.9)
(28.4)

(17.7)
(20.6)
(37.7)
(24.0)

a

Chi-square tests of significance.
The Other race/ethnicity category included designations of ‘‘Other,’’ Asian, Native Hawaiian/Pacific Islander, Native American/Alaska
Native, ‘‘Multi-racial,’’ and Hispanic ethnicity.
c
The Unknown race/ethnicity category included designations of ‘‘Unknown,’’ ‘‘Declined’’ to respond, or data were not recorded.
BMI, body mass index.
b

American women to have received any treatment. However,
women who were White and Other race/ethnicity were as
likely as Black/African American women to have received
any treatment. Insurance status and BMI were not independently associated with receipt of any (vs. no) treatment for
AUB in this model.

Discussion

AUB is a common diagnosis among women in the United
States,1 and was present in 1,784 women of reproductive age
without a diagnosis of cancer seen in our resident clinic
during the study period. We found that among women with

Table 2. Multivariable Logistic Regression Models to Identify Variables Associated with Surgical
(Vs. Medical) Treatment for Abnormal Uterine Bleeding and with Any (Vs. No) Treatment Received
in the Resident Obstetrics & Gynecology Clinic, July 1, 2013 Through June 30, 2017
Characteristics
Age
21–40
41–60
Race/ethnicity
Black/African American
White
Otherb
Unknownc
Insurance type
Public
Self-pay
Private
BMI (kg/m2)
<25
25 to <30
30 to <40
‡40
a

Surgical treatment versus
medical treatment (N = 1,084)

p

Any treatment versus
no treatment (N = 1,705)

pa

1.00 (Reference)
4.82 (3.61–6.43)

<0.001

1.00 (Reference)
0.70 (0.57–0.86)

0.001

1.00 (Reference)
1.23 (0.86–1.76)
0.19 (0.06–0.64)
1.37 (0.77–2.43)

0.26
0.007
0.28

1.00 (Reference)
0.86 (0.67–1.11)
0.68 (0.43–1.06)
0.51 (0.35–0.73)

0.24
0.09
<0.001

1.00 (Reference)
0.74 (0.50–1.08)
0.82 (0.53–1.26)

0.12
0.36

1.00 (Reference)
1.21 (0.93–1.57)
1.09 (0.81–1.47)

0.15
0.57

1.00 (Reference)
1.24 (0.75–2.04)
1.35 (0.86–2.14)
0.91 (0.56–1.48)

0.40
0.20
0.70

1.00 (Reference)
1.30 (0.93–1.80)
1.13 (0.84–1.52)
1.33 (0.97–1.83)

0.12
0.41
0.08

Chi square tests of significance.
The Other race/ethnicity category included designations of ‘‘Other,’’ Asian, Native Hawaiian/Pacific Islander, Native American/Alaska
Native, ‘‘Multi-racial,,’’ and Hispanic ethnicity.
c
The Unknown race/ethnicity category included patient-reported ‘‘Unknown’’ race/ethnicity, ‘‘Declined’’ to respond, or data were not
recorded.
b
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AUB who received treatment during the study period,
race/ethnicity and age were independently associated with
surgical (vs. medical) treatment decisions as well as with any
(vs. no) treatment. BMI and insurance status were not independently associated with surgical treatment or any treatment
for AUB. Our findings from analysis of our resident-clinic
data are discussed in the context of the literature regarding
treatment for noncancer-related AUB.
Our observation that women ages 41–60 who required
treatment were more likely to receive surgical treatment than
medical treatment for their AUB is consistent with knowing
that most of these women have completed childbearing and
may elect for definitive rather than conservative management
options. An alternative reason may be the clinician’s concern
of failing medical treatment in older women due to a possible
occult endometrial cancer. While a diagnosis of cancer was a
reason for exclusion from our study, a recommendation for
surgical treatment may reflect the uncertainty of diagnosis
(such as the potential for an occult endometrial cancer) typical
in evaluation and treatment of women with AUB. Such caution
is consistent with utilizing a diagnosis of AUB rather than a
final pathologic diagnosis as the pivotal decision point for our
analysis. In addition, our finding that women 41–60 were less
likely than women ages 21–40 to receive any treatment reflects
the fact that many older women require only reassurance and
watchful waiting once their evaluation is found to have a low
probability for cancer.3 Although this perimenopausal age
group is less likely to need any treatment, if intervention is
needed, it is more likely to be surgical than medical.
Compared with Black/African American patients, the Other
race/ethnicity group was less likely to receive surgical management than medical management. Although our sample included 17 Asian women, an earlier cross-sectional survey study
analyzing racial disparities in surgical management of benign
gynecologic conditions found that among Asian women, hysterectomy rates were lower.18 Asian women, compared with
White women, were 56% less likely to receive a hysterectomy,
and Black women were 66% more likely to receive a hysterectomy, in separate models fully adjusted for various clinical
and demographic factors.18 This suggests that factors such as
cultural norms and preferences may contribute to the treatment
decision-making process. Our finding that women in the Unknown race/ethnicity group were less likely than Black/African
American women to receive any treatment should be interpreted with caution, as this was a small group that included
patients who were primarily missing data entirely.
As our resident-clinic population includes predominantly
Black/African American patients, we used this larger group
as our reference category in the logistic regression models.
A nonsignificant difference in treatment decisions between
White and Black/African American patients may be due to
the relatively small numbers of White patients in this
resident-clinic patient population or to the shared variance
between race/ethnicity and that of insurance status and BMI,
as there were significant bivariate associations between
race/ethnicity and these variables. Similarly, because very
few patients had private insurance, a significant difference in
treatment choices based on insurance status may not have
been detectable.
We hypothesized that, among women requiring treatment
for AUB, more obese women would be less likely to receive
surgical than medical management secondary to higher po-
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tential for surgical complications and increased technical
difficulty.19,20 However, this hypothesis was not supported,
suggesting that the presence of obesity as a risk factor for
surgical complications did not preclude obese women from
receiving surgery for AUB in the resident clinic. This observation is consistent with other findings in the literature,
indicating that obesity itself is not an independent risk factor
for postoperative morbidity.21,22
Although BMI was not significantly associated with the
odds of receiving surgical (vs. medical) management for AUB,
the association between BMI and any (vs. no) treatment approached significance for women with BMI ‡40 kg/m2. While
our study excluded women with a diagnosis of gynecologic
cancer, clinicians who are presented with an obese patient with
an unclear etiology for AUB may have higher suspicion for
underlying premalignancy or malignancy, and thus favor
treatment over observation. Prior studies have demonstrated an
association between obesity and risk of endometrial hyperplasia or cancer among premenopausal women.23,24 In addition, women with higher BMI may have chronic anovulation,
which is unlikely to spontaneously resolve and therefore necessitate either medical or surgical management. The association between BMI and treatment decisions for AUB is worthy
of further investigation.
A strength of our study lies in the large volume of women
seen in our resident clinic, which yielded a sufficiently large
study sample of women with AUB to allow us to test our
hypotheses. In addition, focusing on patients with a diagnosis
of AUB in the absence of cancer reflects the points of critical
clinical decision making in the care of these patients.
Our study also has limitations. We used data from an administrative database in the OBGYN resident clinic at one,
large, academic medical center. Our study population was
largely Black/African American, 21–40 years old, obese, and
publicly insured. Thus, our findings might not be generalizable to other patient populations. Our study design precluded
examination of temporal relationships. We could not determine whether women who received surgical treatment had
previously declined or failed medical treatment. Using administrative data precludes determination of a definitive
cause for not receiving treatment during this study time
frame. Many patients also might have received care for AUB
elsewhere before entering our clinic system. In addition, we
were unable to determine the exact reason for IUD insertion
or removal, and presumed that this was related to medical
treatment of AUB if contraception was not also coded. Administrative databases, in general, are limited by the type of
data collected and the quality of diagnostic coding by providers; therefore, conclusions based on analyses of these data
must be interpreted with caution.25 A lack of data about comorbidities in our database is also a notable limitation, as
comorbidities will have an impact on the treatment decisionmaking process.
In summary, older patients in the resident clinic who required treatment were more likely to have received surgical
(vs. medical) treatment, but overall less likely to have received any (vs. no) treatment. Women in the Other
race/ethnicity group were less likely than Black/African
American women to receive surgical treatment. Obese women were neither more nor less likely than women with BMI
<25 kg/m2 to receive surgical treatment or to receive any
treatment. BMI and insurance status were not independently
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associated with treatment for AUB. Additional studies in
larger and more diverse populations are warranted to assess
whether obesity and other unmeasured variables are associated with treatment decisions for women with AUB, and if
there are health care disparities in those decisions based on
specific patient characteristics, such as race/ethnicity and
BMI. The role of bias in treatment decisions leading to
health care disparities also warrants investigation. Prospective studies would allow further insight into the care of
women with AUB, especially among patients who receive
multiple different treatments or who proceed to surgical
management after medical management options have been
exhausted.
Conclusions

Management of AUB differed significantly by age and
race/ethnicity but not by BMI and insurance type. In this
resident-clinic sample, women 41–60 years of age who required treatment were, not surprisingly, more likely to receive surgical treatment, although they were less likely to
receive any (vs. no) treatment for AUB. To our knowledge,
this study is the first to investigate the care of women of
reproductive age with the broad diagnosis of AUB (excluding
a cancer diagnosis) using an administrative database, and
thus expands the literature on an understudied gynecologic
topic and on health care disparities in treatment for women
with AUB. Although our study examined patient characteristics that could be associated with healthcare disparities in
AUB treatment, additional research is needed. To aid in future research about this topic, providers should clearly document their clinical decision-making process in management
decisions, specifically if patients have exhausted or declined
medical management options before proceeding to surgery
and if comorbidities were considered in the choice of management options for AUB. Administrative databases are notoriously limited in this regard. Thus, planned data collection
to answer research questions such as ours regarding potential
disparities in clinical-management decisions for AUB are
still needed, using a larger and more diverse sample of patients and examining clinical-treatment decisions in relation
to other social determinants of health.
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